Adults 18 – 65 yrs with Schizophrenia – Risperidone Extended-Release Injectable Suspension for Subcutaneous Use as Maintenance
The patient has a diagnosis of schizophrenia for >1 year and has had ≥1 episode of relapse in the last 24 months. Some Inclusion Criteria:
- The patient has been responsive to an antipsychotic treatment (other than clozapine) in the past year based on discussions with family members or healthcare professionals.
Some Exclusion Criteria:
- The patient has a current clinically significant Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, or amnestic or other cognitive disorders, or borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
- The patient is currently on clozapine or received electroconvulsive therapy in the last 12 months.
- The patient has a history of epilepsy or seizures, neuroleptic malignant syndrome, tardive dyskinesia, or other medical condition that would expose the patient to undue risk.
- The patient has a positive serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B surface antigen, and/or hepatitis C.
Adolescents 12 – 17 yrs with Schizophrenia
Clinical Biospecimen Procurement to Support Advancements in Medical Diagnoses of Diseases
- 18 yrs or older
- Must be diagnosed with Lewy Body Dementia, Dementia with Psychosis, Corticobasal Syndrome or Progressive Supranuclear Palsy